3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
9
Esophageal Squamous Cell Carcinoma
5
Neoplasm Metastasis
4
Carcinoma, Hepatocellular
4
Advanced Solid Tumors
4
Recurrence
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Solid Tumors
1
Sarcoma
1
Neuroendocrine Tumors
1
Nasopharyngeal Neoplasms
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lung Neoplasms
1
Locally Advanced or Metastatic Urothelial Bladder Cancer
1
Interventions
Gemcitabine
47
Cisplatin
32
pembrolizumab
28
Paclitaxel
13
Docetaxel
13
avelumab
12
Mitomycin
12
atezolizumab
11
Nivolumab
11
Cystectomy
10
Carboplatin
9
durvalumab
7
Sunitinib
7
apaziquone
6
Doxorubicin
6
BCG Vaccine
6
5-aminolevulinic acid hexyl ester
6
Vinblastine
5
Radiation
5
Platinum
5
Methotrexate
5
Magnetic Resonance Spectroscopy
5
Albumin-Bound Paclitaxel
5
Taxes
4
Standard of Care
4
Sorafenib
4
Radiotherapy
4
Fluorouracil
4
Erlotinib Hydrochloride
4
1,2-diaminocyclohexaneplatinum II citrate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Urinary Bladder Neoplasms
×
tislelizumab
×
Clear all
No trials found.